Viatris (VTRS) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Which has better earnings & valuation, TAK or VTRS?

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.20B	1.50	$994.06M	$0.40	33.31
Viatris	$15.43B	0.84	$54.70M	-$0.74	-14.72

Does the media prefer TAK or VTRS?

In the previous week, Takeda Pharmaceutical had 10 more articles in the media than Viatris. MarketBeat recorded 13 mentions for Takeda Pharmaceutical and 3 mentions for Viatris. Takeda Pharmaceutical's average media sentiment score of 0.58 beat Viatris' score of 0.48 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals hold more shares of TAK or VTRS?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is TAK or VTRS a better dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 4.0%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.4%. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -64.9% of its earnings in the form of a dividend. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do analysts rate TAK or VTRS?

Viatris has a consensus target price of $13.67, suggesting a potential upside of 25.50%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Viatris	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community prefer TAK or VTRS?

Takeda Pharmaceutical received 78 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 35.48% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Viatris	Outperform Votes 22 35.48%	Underperform Votes 40 64.52%

Which has more volatility & risk, TAK or VTRS?

Takeda Pharmaceutical has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Is TAK or VTRS more profitable?

Takeda Pharmaceutical has a net margin of 4.53% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.53%	9.39%	4.53%
Viatris	-5.87%	16.46%	7.09%

Summary

Takeda Pharmaceutical and Viatris tied by winning 10 of the 20 factors compared between the two stocks.